Abstract:Abstract Purpose Primary melanoma of the esophagus (PMME) is a highly uncommon disease. In this retrospective study, we analyzed the pathogenesis, pathology, treatment outcomes, prognosis, and radiologic findings of PMME. The aim of this study is to characterize the clinical features of PMME and provide a comprehensive view of the immunotherapy treatment outcomes, with the goal of further understanding the disease Materials and methods We retrospectively searched our hospital from 2009 to 2023 revealed 14 patients with pathologically confirmed PMME, whose clinical features contain immunohistochemical results and image finding were available for review. Medical records were reviewed for treatment efficacy and clinical manifestations. Results 14 patients with pathologically confirmed PMME were included, 8 patients died a mean of 8 months afterward irrespective of therapeutic modalities, and 3 was alive more than 1 years, while 5 were lost to follow-up. The most common symptom was dysphagia (92.8%,13/14), Before surgery 11 patients underwent contrast material–enhanced chest computed tomographic (CT) scans, 1 only underwent barium esophagogram, and one underwent both CT and barium esophagogram. One patient underwent preoperative PET-CT, one patient received postoperative PET-CT. Chest CT or esophagography/gastroscope which showed located in the middle (n = 8), distal (n = 5), or proximal (n = 1). The median age of patients was 57years (range: 45–77 years), and 85.7% (12/14) of patients were male. 12 patients underwent esophagogastrostomy and 7 (58.3%) of them were found with lymph node metastasis. The routine histology using immunohistochemical staining exhibiting strong reactivity for S-100, and HMB-45 proteins and PCK negative. One patient presented with lung metastases at the time of esophageal surgery, while the remaining patients not had extra-esophagus metastases before surgery. Postoperative pathology revealed tumor diameter ranging from 2-9cm. Adjuvant chemotherapy was performed in 9 patients, and 2 received extra postoperative adjuvant radiotherapy ,5 plus immunotherapy. One patient only received postoperative radiotherapy. Overall survival (OS) in all patient who received surgery (9 of 12) was 7.4 months, despite received adjuvant therapy, most patients (6/9) relapse shortly after surgery and median disease-free time (DFS) 6.1 months. Surprisingly, a patient(case 13) with lymph node metastasis survived more than 2 years after receiving adjuvant immunotherapy(adjuvant anti-PD-1 immunotherapy: Pembrolizumab) besides 5 of 9 received additional immunotherapy are more inclined to have a favorable prognosis. Conclusion Primary malignant melanoma of the esophagus is a very rare in this localization. Preoperative radiologically finding and endoscopic biopsy difficult to distinguish from other esophageal malignancies. PMME inclined to with lymph node metastasis despite earlier T stage. The prognosis is dismal for rapid progression despite resection. Traditional adjuvant therapy seems not appear to confer a survival benefit, but adjuvant immunotherapy may improve efficacy after patients received chemoradiation, which warrant for future studies.

Results of Surgical Treatment for Primary Malignant Melanoma of the Esophagus: A Multicenter Retrospective Study.

Clinical Outcome of Primary Malignant Melanoma of the Esophagus: a Single-Institute Retrospective Analysis

Clinical Outcome of primary malignant melanoma of the esophagus：a single-center experience

Primary Malignant Melanoma in Gastroesophageal Junction with 36 Months' Recurrence-Free: a Case Report.

Primary Malignant Melanoma of the Esophagus: a Population-Based Study

Primary Malignant Melanoma of the Esophagus: a Study of Clinical Features, Pathology, Management and Prognosis

[Clinical Pathological Features of 180 Cases with Primary Esophageal Malignant Melanoma].

Primary Malignant Melanoma of the Esophagus: A Retrospective Analysis of Clinical Features, Management, and Survival of 76 Patients

Clinicopathological Features, Staging Classification, and Clinical Outcomes of Esophageal Melanoma: Evaluation of a Pooled Case Series

Primary malignant melanoma of the esophagus: Clinical features, signaling pathway, management, and survival.

Comprehensive Molecular Findings in Primary Malignant Melanoma of the Esophagus: A Multicenter Study

Primary malignant melanoma of the esophagus: A case report and review of the literature

Clinical analysis of primary malignant melanoma of esophagus

Primary Malignant Melanoma of Esophagus: Report of Four Cases and Review of the Literatures

Epidemiology and Survival Outcomes for Eyelid Primary Malignant Melanoma: an Analysis of 1397 Cases in the SEER Database

A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus

Investigation To Metastasis Of Regional Lymph Node Station And Prediction To Long-Term Survival Following Esophagectomy In Thoracic Esophageal Cancer With Stage T1 To T3.

Multimodality Therapy and Survival Outcomes in Resectable Primary Small Cell Carcinoma of the Esophagus: A Multicenter Retrospective Study

Longitudinal genomic alternations and clonal dynamics analysis of primary malignant melanoma of the esophagus

Malignant melanoma of the esophagus complicated with poorly differentiated mucinous adenocarcinoma of the stomach: A case report.

[Surgical Treatment and Prognostic Analysis of 109 Patients with Primary Esophageal Small Cell Carcinoma].